Pharvaris N.V. (PHVS) Presents At Cantor Global Healthcare Conference 2025 Transcript

Group 1 - Pharvaris is developing deucrictibant, a promising molecule for Hereditary Angioedema (HAE) [2] - The presentation features key executives from Pharvaris, including CCO Wim Souverijns and CMO Peng Lu [1] - The session aims to provide insights into the current state of affairs at Pharvaris and engage in a Q&A format [2]